AARHUS, Denmark, July 4, 2013 /PRNewswire/ --
Unisense FertiliTech, world leader in time-lapse technology for IVF announce they will present a large scale analysis of embryo development variables which are linked to implantation potential at the European Society of Human Reproduction and Endocrinology (ESHRE) in London July 7th until 10th. These results will be presented at the Unisense FertiliTech exhibit.
Many clinics using the EmbryoScope™ time-lapse system provide information about embryo development and clinical treatment outcome to Unisense FertiliTech´s database. This database is the largest of its kind and contains detailed information on embryo development characteristics in relation to implantation and successful pregnancy.
Based on an agreement with 40 clinics comprising 12,000 transferred embryos, a detailed analysis of 8,000 embryos with known implantation outcome was performed. The analysis revealed clear variables, which could be used to help select better embryos for day 2, 3 or 5 transfer. Furthermore, the strength of the aneuploidy risk algorithm, recently reported by the CARE Fertility group in the journal RBMonline (Campbell et al, Reprod.Biomed. Online 2013 May; 26(5):477-85.) was tested against a large dataset and it confirmed the findings.
Bjørn Molt Petersen and Mette Lægdsmand, data analysis experts at FertiliTech, state "Although this analysis appears to show convincing trends that are linked to embryo development potential, the analysis also reveals the impact of different culture conditions and practices between clinics. This means that the actual criteria for good embryo quality needs to be individually validated prior to use".
Unisense FertiliTech who celebrates 10 years in developing innovative technologies to improve embryo selection in the IVF laboratory has developed and manufactures the EmbryoScope™ time-lapse system. The system was cleared for clinical use in Europe in 2009 and is the only time-lapse system which is FDA cleared for clinical use in the USA. The technology is used in routine clinical practice by more than 275 clinics worldwide and has been used in approximately 60,000 treatment cycles. It is estimated that more than 10,000 babies have been born using the EmbryoScope™ system.
In order to allow clinics to utilize the full potential of time-lapse technology, Unisense FertiliTech continues to develop embryo analysis software to improve outcomes in IVF. Chief Scientific Officer Niels Birger Ramsing states "very early on, we recognized the need for software tools which will allow clinics to customize their own evaluation models in their clinics, that is why we are at the forefront of delivering such tools to help our customers make the best decisions".
About Unisense FertiliTech A/S:
Unisense FertiliTech A/S was founded in 2003 to develop technology to improve human embryo assessment in assisted reproduction. Unisense FertiliTech has developed, and manufactures the EmbryoScope™ time- lapse system, facilitating improved IVF treatment, flexible work routines and effective communication through comprehensive documentation of embryo development and evolving improvements in selection. The System is FDA 510(k) cleared and CE marked as a Class II medical device.
Our Mission is to help infertile couples achieve their dream of parenthood through development of novel technology, quantification and digitized documentation. "The Vision to Conceive"
Unisense FertiliTech A/S
SOURCE Unisense Fertilitech A/S